Eleonora Lekova, Wioleta M Zelek, David Gower, Claus Spitzfaden, Isabelle H Osuch, Elen John-Morris, Lasse Stach, Darren Gormley, Andrew Sanderson, Angela Bridges, Elizabeth R Wear, Sebastien Petit-Frere, Michael N Burden, Richard Priest, Trevor Wattam, Semra J Kitchen, Maria Feeney, Susannah Davis, B Paul Morgan, Eva-Maria Nichols
Myasthenia Gravis (MG) is mediated by autoantibodies against acetylcholine receptors that cause loss of the receptors in the neuromuscular junction. Eculizumab, a C5-inhibitor, is the only approved treatment for MG that mechanistically addresses complement-mediated loss of nicotinic acetylcholine receptors. It is an expensive drug and was approved despite missing the primary efficacy endpoint in the Phase 3 REGAIN study. There are two observations to highlight. Firstly, further C5 inhibitors are in clinical development, but other terminal pathway proteins, such as C7, have been relatively understudied as therapeutic targets, despite the potential for lower and less frequent dosing...
2022: Frontiers in Immunology